JW (Cayman) Therapeutics Co. Ltd. (JNY) Financial Statements
JW (Cayman) Therapeutics Co. Ltd. Financial Overview
JW (Cayman) Therapeutics Co. Ltd.'s market cap is currently $105.27M. The company's EPS TTM is $-0.80; its P/E ratio is -2.35; JW (Cayman) Therapeutics Co. Ltd. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 276.31M | $ 158.22M | $ 173.86M | $ 145.70M | $ 30.80M |
| Gross Profit | $ 118.91M | $ 77.32M | $ 88.22M | $ 58.76M | $ 9.04M |
| Operating Income | $ -241.71M | $ -459.28M | $ -789.61M | $ -855.88M | $ -759.08M |
| EBITDA | $ -159.83M | $ -369.37M | $ -655.75M | $ -752.27M | $ -723.49M |
| Net Income | $ -540.92M | $ -590.62M | $ -768.00M | $ -846.13M | $ -702.33M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 503.28M | $ 762.53M | $ 1.01B | $ 1.39B | $ 1.84B |
| Total Assets | $ 987.32M | $ 1.68B | $ 2.15B | $ 2.79B | $ 3.12B |
| Total Debt | $ 262.67M | $ 422.40M | $ 318.80M | $ 279.13M | $ 147.03M |
| Net Debt | $ -240.61M | $ -334.97M | $ -687.11M | $ -1.10B | $ -1.69B |
| Total Liabilities | $ 430.82M | $ 511.20M | $ 462.26M | $ 437.06M | $ 325.75M |
| Stockholders' Equity | $ 556.50M | $ 1.17B | $ 1.68B | $ 2.35B | $ 2.79B |
| Cash Flow | |||||
| Free Cash Flow | $ -78.46M | $ -348.87M | $ -413.00M | $ -613.60M | $ -634.28M |
| Operating Cash Flow | $ -76.85M | $ -333.44M | $ -398.42M | $ -536.72M | $ -561.20M |
| Investing Cash Flow | $ -1.49M | $ -15.43M | $ 9.90M | $ -124.08M | $ -137.13M |
| Financing Cash Flow | $ -169.81M | $ 90.49M | $ 275.00K | $ 112.35M | $ -30.62M |
Currency in CNY